Patrick Lamy - Jan 10, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Senior Vice President, Commercial Strategy
Signature
/s/ Jonathan Young, attorney-in-fact
Stock symbol
AKRO
Transactions as of
Jan 10, 2023
Transactions value $
$0
Form type
4
Date filed
1/11/2023, 06:51 PM
Next filing
Dec 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 -100K -50% $0.00 100K Jan 10, 2023 Common Stock 100K $44.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on January 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Senior Vice President, Commercial Strategy